Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
NCT00655252 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2011-08-19
Summary
This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.
Conditions
- Metastatic Renal Cell Cancer
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- Australia
- Austria
- Belgium
- Canada
- Czechia
- Germany
- Hungary
- Lebanon
- Norway
- Switzerland
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
NCT00410124 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00331409 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
NCT00651482 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT00903175 ·Status: COMPLETED ·Phase: PHASE2
-
Sequential Therapy in Metastatic Renal Cell Carinoma
NCT01731158 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
NCT00422344 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
NCT01206764 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
NCT00719264 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
NCT01715935 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib and RAD001 Renal Cell Carcinoma
NCT00384969 ·Status: COMPLETED ·Phase: PHASE1
-
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
NCT00392821 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
NCT01034631 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT01266837 ·Status: COMPLETED ·Phase: PHASE4
-
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
NCT00323739 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
NCT01514448 ·Status: COMPLETED ·Phase: PHASE4
-
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
NCT01582009 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
NCT00715182 ·Status: COMPLETED ·Phase: PHASE1
-
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
NCT02406521 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
NCT00942682 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
NCT01136733 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
NCT00827359 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
NCT01888042 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
NCT00353301 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
NCT00788060 ·Status: COMPLETED ·Phase: PHASE1
-
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
NCT04895748 ·Status: TERMINATED ·Phase: PHASE1